{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:58:44Z","timestamp":1787507924627,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boston Scientific","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Water vapor thermal therapy (WVTT) is a minimally invasive procedure for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). There are no known systematic reviews reporting the effectiveness and safety of this increasingly common BPH therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic review and meta-analysis of studies utilizing WVTT for symptomatic BPH. The international prostate symptom score (IPSS), IPSS-quality of life (IPSS-QOL), BPH impact index (BPHII), and maximum flow rate (Qmax) were calculated as the weighted mean difference relative to baseline and reported in minimal clinically important difference (MCID) units. MCID thresholds were \u22123 for IPSS, \u22120.5 for IPSS-QOL, \u22120.5 for BPHII, and 2\u200amL\/s for Qmax. The surgical retreatment rate was calculated using life-table methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 5 cohorts treated with WVTT from 4 studies (514 patients; 40% with median lobe obstruction) with 2 years median follow-up (range: 6 months to 4 years). The IPSS, IPSS-QOL, BPHII, and Qmax significantly improved at all intervals between 3 months and 4 years; this benefit ranged from 3.3 to 3.8 MCID units for IPSS, 3.9 to 4.6 MCID units for IPSS-QOL, 6.8 to 8.2 MCID units for BPHII, and 1.5 to 3.0 MCID units for Qmax. The surgical retreatment rate was 7.0% at 4 years of follow-up data. Most adverse events were nonserious and transient; dysuria, urinary retention, and urinary tract infection were most common. No cases of de novo erectile dysfunction occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>WVTT provided improvement in BPH symptoms that exceeded established MCID thresholds, preserved sexual function, and was associated with low surgical retreatment rates over 4 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000021365","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T19:08:31Z","timestamp":1595358511000},"page":"e21365","source":"Crossref","is-referenced-by-count":31,"title":["Water vapor thermal therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1885","authenticated-orcid":false,"given":"Larry E.","family":"Miller","sequence":"first","affiliation":[{"name":"Miller Scientific, Johnson City, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Chughtai","sequence":"additional","affiliation":[{"name":"Department of Urology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McVary","sequence":"additional","affiliation":[{"name":"Center for Male Health, Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo R.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirikan","family":"Rojanasarot","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"DeRouen","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)35405-8","article-title":"The prevalence of prostatism: a population-based survey of urinary symptoms","volume":"150","author":"Chute","year":"1993","journal-title":"J Urol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/JU.0000000000000499","article-title":"Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project","volume":"203","author":"Welliver","year":"2019","journal-title":"J Urol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","volume":"68","author":"Cindolo","year":"2015","journal-title":"Eur Urol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ijcp.12241","article-title":"Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"68","author":"Koh","year":"2014","journal-title":"Int J Clin Pract"},{"key":"R6-20230915","first-page":"639","article-title":"Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"69","author":"Zabkowski","year":"2018","journal-title":"J Physiol Pharmacol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/JU.0000000000000319","article-title":"Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019","volume":"202","author":"Foster","year":"2019","journal-title":"J Urol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.juro.2018.05.048","article-title":"Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline","volume":"200","author":"Foster","year":"2018","journal-title":"J Urol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","article-title":"Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study","volume":"126","author":"McVary","year":"2019","journal-title":"Urology"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.juro.2012.08.257","article-title":"Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms","volume":"189","author":"Barry","year":"2013","journal-title":"J Urol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1477-7525-11-211","article-title":"Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability for decision-makers","volume":"11","author":"Johnston","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-8-116","article-title":"Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units","volume":"8","author":"Johnston","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","article-title":"Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"197","author":"Roehrborn","year":"2017","journal-title":"J Urol"},{"key":"R20-20230915","first-page":"207","article-title":"Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia","volume":"8","author":"Dixon","year":"2016","journal-title":"Res Rep Urol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jsxm.2016.03.372","article-title":"Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study","volume":"13","author":"McVary","year":"2016","journal-title":"J Sex Med"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","article-title":"Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"195","author":"McVary","year":"2016","journal-title":"J Urol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","article-title":"Three-year outcomes of the prospective, randomized controlled Rezum system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"111","author":"McVary","year":"2018","journal-title":"Urology"},{"key":"R24-20230915","first-page":"159","article-title":"Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"9","author":"Darson","year":"2017","journal-title":"Res Rep Urol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41391-017-0022-9","article-title":"Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience","volume":"21","author":"Mollengarden","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bju.12745","article-title":"Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK","volume":"115","author":"Speakman","year":"2015","journal-title":"BJU Int"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","article-title":"Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"67","author":"Perera","year":"2015","journal-title":"Eur Urol"},{"key":"R28-20230915","first-page":"8802","article-title":"Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can J Urol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CEOR.S148195","article-title":"Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"10","author":"Ulchaker","year":"2018","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:04:13Z","timestamp":1694811853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021365"}},"subtitle":["Systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":27,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021365","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}